Summit Therapeutics reports preliminary cash ≥$410M as of Dec 31, 2024

Summit Therapeutics Inc.

Preliminary unaudited cash, cash equivalents, and short-term investments at least $410M.
Includes repayment of $31.8M related party loan (principal + interest) previously outstanding.
Amount is preliminary and subject to completion of year-end financial closing procedures.
Company presenting at J.P. Morgan Healthcare Conference on January 13, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.